LOGIN  |  REGISTER
C4 Therapeutics

Owens & Minor Announces Upcoming Investor Day on December 6th

November 29, 2023 | Last Trade: US$9.00 0.29 -3.12

RICHMOND, Va. / Nov 29, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) (the “Company”) today announced that it will host an Investor Day for investors and research analysts on Wednesday, December 6th at Convene in Boston, Massachusetts. The event will feature presentations from members of the senior executive leadership team, who will share the Company’s strategic vision, operating and growth strategy, and multi-year financial targets.

The event will begin at 8:30 a.m. Eastern Standard Time (EST) and is expected to conclude at 12:00 p.m. EST. Due to limited capacity, in-person attendance is by invitation only. A live broadcast and on-demand replay of the event will be available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers, and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at https://www.linkedin.com/company/owens-&-minor/.

Astria Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page